Investment Opportunities in APIs-KSMs-Drug Intermediates Bulk Drug Industries.

Description:

InvestmentOpportunities in APIs-KSMs-Drug Intermediates Bulk Drug Industries. Cabinet Approves Promotion ofDomestic Manufacturing of Critical Key Starting Materials-Drug Intermediatesand Active Pharmaceutical Ingredients in the Country.

Key Starting Materials (KSMs)/Drug Intermediates

KSMsfrom the essentialmedicines list for strategic reasons posed by the COVID-19.

Role of Government towards(KSMs)/Drug Intermediates

TheUnion Cabinet chaired by the Prime Minister, Shri Narendra Modi has approvedthe following schemes:

Thescheme on Promotion of BulkDrugParks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks withfinancial implication of Rs. 3,000 crore for next five years.

ProductionLinked Incentive (PLI) Scheme for promotion of domestic manufacturing ofcritical KSMs/DrugIntermediates and APIs in the country with financialimplications of Rs6, 940 crore for next eight years.

Keywords: #Levofloxacin #Sulfadiazine #Ciprofloxacin #Ofloxacin #Norfloxacin #Artesunate #Telmisartan #Losartan #Valsartan #Olmesartan #Atorvastatin #Acyclovir #Lopinavir #Ritonavir #Oxcarbazepine #Carbamazepine #Levodopa #Carbidopa #Levetiracetam #Aspirin #Diclofenac Sodium #Tinidazole #Ornidazole #businessopportunity #projectreport #DetailedProjectReport #businessconsultant #businessfeasibilityreport #BusinessPlan #startyourbusiness #investmentopportunity #growyourbusiness #startups #business #covidbu